Clinic Roundup

• Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase IIb study testing EPI-743 in patients with Friedreich's ataxia. The six-month study, expected to be followed by an extension phase, will enroll patients between the ages of 18 and 45 who possess genetic confirmation of Friedreich's ataxia.